IL5 and Alzheimer disease: found that in AD mice, the Mdivi‐1 treatment could improve the AD‐like symptoms of mice, as manifested by the reduction of serum IgE levels, the thickening of the epidermis, the infiltration of mast cells, and the reduced production of IL‐4, IL‐5 and IL‐13.